Seroconversion rate after vaccination against COVID-19 in patients with cancer-a systematic review.
Seroconversion rate after vaccination against COVID-19 in patients with cancer-a systematic review.
复制标题
癌症患者对COVID-19的疫苗接种后的血清转化率 - 系统评价。
DOI：
10.1016/j.annonc.2021.10.014
复制
发表时间：
2022-03
期刊：
影响因子：
--
通讯作者：
Curigliano G
中科院分区：
文献类型：
--
作者：
Corti C;Antonarelli G;Scotté F;Spano JP;Barrière J;Michot JM;André F;Curigliano G
冠状病毒病2019年(新冠肺炎)已影响到全球2.1亿人。到目前为止，新冠肺炎的最佳治疗方法仍不确定。由于癌症病史与新冠肺炎导致的较高死亡率有关，因此在这些患者中建立安全有效的疫苗覆盖范围至关重要。然而，癌症患者(PSC)大多被排除在候选疫苗的临床试验之外。本系统综述旨在调查新冠肺炎疫苗在PSC中免疫原性的现有证据。所有评估严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)疫苗安全性和有效性的前瞻性研究都包括在内，如果有的话，第一次和第二次接种后的免疫原性是主要终点。在制定了良好的接种计划后，针对新冠肺炎的PSC疫苗似乎总体上是安全的和免疫原性的。然而，与普通人群相比，血清转换率仍然较低、落后或两者兼而有之。恶性血液病患者，特别是那些在过去12个月内接受B细胞耗尽剂治疗的患者，血清转换不良的风险最大。对于PSC，可以提出一种量身定制的疫苗接种方法，特别是根据恶性肿瘤的类型和接受的特定肿瘤治疗。
Coronavirus disease 2019 (COVID-19) has affected >210 million people worldwide. An optimal therapeutic approach for COVID-19 remains uncertain, to date. Since the history of cancer was linked to higher mortality rates due to COVID-19, the establishment of a safe and effective vaccine coverage is crucial in these patients. However, patients with cancer (PsC) were mostly excluded from vaccine candidates' clinical trials. This systematic review aims to investigate the current available evidence about the immunogenicity of COVID-19 vaccines in PsC. All prospective studies that evaluated the safety and efficacy of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were included, with immunogenicity after the first and the second dose as the primary endpoint, when available. Vaccination against COVID-19 for PsC seems overall safe and immunogenic after well-conducted vaccination schedules. Yet the seroconversion rate remains lower, lagged or both compared to the general population. Patients with hematologic malignancies, especially those receiving B-cell-depleting agents in the past 12 months, are the most at risk of poor seroconversion. A tailored approach to vaccination may be proposed to PsC, especially on the basis of the type of malignancy and of the specific oncologic treatments received.
登录
查看更多内容
影响因子：
6.5
作者：
Benda, Magdalena;Mutschlechner, Beatrix;Winder, Thomas
通讯作者：
Winder, Thomas
影响因子：
8.4
作者：
Elkrief, Arielle;Desilets, Antoine;Routy, Bertrand
通讯作者：
Routy, Bertrand
影响因子：
51.1
作者：
Garassino, Marina Chiara;Whisenant, Jennifer G.;Horn, Leora
通讯作者：
Horn, Leora
影响因子：
28.2
作者：
Bilich, Tatjana;Roerden, Malte;Walz, Juliane S.
通讯作者：
Walz, Juliane S.
DOI：
10.1056/nejmoa2114255
发表时间：
2021-10-07
期刊：
The New England journal of medicine
影响因子：
--
作者：
Bar-On YM;Goldberg Y;Mandel M;Bodenheimer O;Freedman L;Kalkstein N;Mizrahi B;Alroy-Preis S;Ash N;Milo R;Huppert A
通讯作者：
Huppert A